KRAS Inhibitors Reshape the Treatment Landscape in Pancreatic Cancer
This review synthesizes the emerging efficacy and safety data for direct and indirect KRAS-targeted agents in pancreatic ductal adenocarcinoma, a field with historically minimal systemic options.
KRAS: From 'undruggable' to potential target in pancreatic cancer.
Over 90% of pancreatic ductal adenocarcinoma cases involve KRAS mutations, making them critical targets for therapeutic innovation. Emerging agents like MRTX1133 and RMC-9805 show promising preclinical results against KRAS G12D mutations in pancreatic cancer. While current KRAS inhibitors have limited efficacy in practice, combining them with other agents offers a potential path forward. Limitations include resistance and the need for more clinical data. New KRAS-targeted therapies may offer hope in pancreatic cancer, though challenges like resistance require innovative approaches.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.
Authors:Khan N, Raza U, Ali Zaidi SA, Nuer M, Abudurousuli K, Paerhati Y, Aikebaier A, Zhou W
Citation:Khan N, Raza U, Ali Zaidi SA, et al. Drugging the 'undruggable' KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer. Cancer biology & medicine. 2025;22(7):762-88. doi:10.20892/j.issn.2095-3941.2025.0122
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Want the full analysis?
Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.